Analyst Rating
based on 21 analysts
38.10%
Buy
28.57%
Hold
33.33%
Sell
Based on 21 analysts offering long term price targets for Alkem Laboratories Ltd. An average target of ₹5583.24
Source: S&P Global Market Intelligence
Alkem Laboratories Ltd Share analysis
Alkem Laboratories Ltd price forecast by 21 analysts
Downside of
High
₹6833
Target
₹5583.24
Low
₹3960
Alkem Laboratories Ltd target price ₹5583.24, a slight downside of -10.19% compared to current price of ₹6090.3. According to 21 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alkem Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:20.18%
Forecast
Actual
Including amortisation and stock based compensations
Alkem Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:41.17%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹6,050₹6,25552 Week's Low
52 Week's High
₹3,447₹6,439.9
| Returns % | |
| 1 Month Return | + 8.29 % |
| 3 Month Return | + 19.14 % |
| 1 Year Return | + 69.86 % |
| Market Stats | |
| Previous Close | ₹6,216.85 |
| Open | ₹6,244.95 |
| Volume | 1.12L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹74,331.77Cr |
Key Statistics
| P/E Ratio | 36.18 |
| PEG Ratio | 0.47 |
| Market Cap | ₹74,331.77 Cr |
| P/B Ratio | 5.6 |
| EPS | 151.52 |
| Dividend Yield | 0.81 |
| Sector | Pharmaceuticals |
| ROE | 17.56 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹74,331.77 Cr | 45.57% | 0.56 | ₹1,811 Cr | ₹12,667 Cr | |
| HOLD | ₹27,441.61 Cr | 33.21% | 0.55 | ₹362 Cr | ₹2,226 Cr | |
| HOLD | ₹27,030.75 Cr | 124.4% | 0.67 | ₹168 Cr | ₹5,040 Cr | |
| BUY | ₹9,341.71 Cr | 9.36% | 0.64 | ₹119 Cr | ₹547 Cr | |
| BUY | ₹4,533.01 Cr | 16.24% | 0.54 | ₹69 Cr | ₹571 Cr |
Company Information
With its headquarters in Mumbai, India, Alkem Laboratories is engaged in the manufacture of a wide range of pharmaceutical products across multiple therapeutic categories, including cardiovascular, central nervous system, gastro-intestinal, anti-infective, diabetology, and nutrition. The company has a strong presence in the Indian market and exports its products to over 50 countries.
Share Price: ₹6090.30 per share as on 18 Sep, 2024 04:01 PM
Market Capitalisation: ₹74,331.77Cr as of today
Revenue: ₹3,031.82Cr as on June 2024 (Q2 24)
Net Profit: ₹550.24Cr as on June 2024 (Q2 24)
Listing date: 23 Dec, 2015
Chairperson Name: Basudeo N Singh
| Organisation | Alkem Laboratories Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Alkem Laboratories Ltd
Alkem Labs Pursues Acquisition of JB Pharma - 13 Sep, 2024
Alkem Laboratories is reportedly looking to acquire JB Chemicals and Pharmaceuticals as private equity firm KKR and others seek to exit their investments. The promoters are collaborating with Nomura to find potential buyers for their stake.
Alkem Promoters Explore Stake Sale to PE Firms - 12 Sep, 2024
Alkem Laboratories' promoters are considering selling their 56.38% stake, valued at Rs 42,283 crore, to private equity firms like KKR, Blackstone, and EQT. The company reported a 90.1% increase in net profit and a 56.4% rise in EBITDA for Q1 FY25, indicating strong financial performance.
Alkem Signs Licensing Deal with Takeda Pharmaceuticals - 03 Sep, 2024
Alkem Laboratories has entered a patent licensing agreement with Takeda to commercialize Vonoprazan in India. Analysts maintain a neutral outlook, citing operational margin improvements and long-term growth strategies.
Stake Sale by Promoter Entity in Alkem Laboratories - 23 Aug, 2024
A promoter entity of Alkem Laboratories sold a 0.71% stake at an average price of Rs 5,732.15 per share. Additionally, Alkem MedTech signed an agreement with Exactech for joint replacement implants manufacturing in India.
Alkem Laboratories Sees Stake Sales and Profit Surge - 22 Aug, 2024
Alkem Laboratories' promoter plans to sell a 0.7% stake, while the company reports a significant profit increase in Q1 FY25. A shareholder also sold a 0.71% stake for Rs 487.2 crore.
Alkem Labs Promoter Plans Stake Sale at Discount - 21 Aug, 2024
The promoter of Alkem Laboratories Ltd is set to sell a 0.7% stake through block deals at a floor price of ₹5,616, reflecting a 3% discount. The company reported a nearly 90% profit jump in Q1, with significant growth in domestic sales.
Insights on Alkem Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 11.92% to 14.73% in Jun 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 293.56 Cr → 545.16 Cr (in ₹), with an average increase of 46.2% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 3.02K Cr → 3.15K Cr (in ₹), with an average increase of 4.1% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 146.7% return, outperforming this stock by 82.6%
- NO EFFECT
Against Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 83.3% return, outperforming this stock by 13.4%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 56.74% to 56.38% in Jun 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, ALKEM stock has moved down by -1.0%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 18.52% to 16.36% in Jun 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 9.11% to 8.69% in Jun 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 56.38% | ||
| Foreign Institutions | 8.69% | ||
| Mutual Funds | 14.72% | 23.49 | |
| Retail Investors | 16.36% | ||
| Others | 3.85% | 3.88 |
Key Indicators
Alkem Laboratories Ltd Valuation
Alkem Laboratories Ltd in the last 5 years
Lowest (20.07x)
March 24, 2021
Today (36.18x)
September 17, 2024
Industry (58.70x)
September 17, 2024
Highest (44.21x)
August 9, 2023
Earnings and Dividends
Alkem Laboratories Ltd Earnings Results
Alkem Laboratories Ltd’s net profit jumped 90.13% since last year same period to ₹545.16Cr in the Q1 2024-2025. On a quarterly growth basis, Alkem Laboratories Ltd has generated 85.71% jump in its net profits since last 3-months.
Read More about Earnings ResultsAlkem Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Alkem Laboratories Ltd has declared dividend of ₹5 - translating a dividend yield of 0.64%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Alkem Laboratories Ltd is currently in a Neutral trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Alkem Laboratories Ltd shares.
Alkem Laboratories Ltd (ALKEM) share price today is ₹6090.3
Alkem Laboratories Ltd is listed on NSE
Alkem Laboratories Ltd is listed on BSE
- Today’s highest price of Alkem Laboratories Ltd is ₹6255.
- Today’s lowest price of Alkem Laboratories Ltd is ₹6050.
PE Ratio of Alkem Laboratories Ltd is 36.18
PE ratio = Alkem Laboratories Ltd Market price per share / Alkem Laboratories Ltd Earnings per share
Today’s traded volume of Alkem Laboratories Ltd(ALKEM) is 1.12L.
Today’s market capitalisation of Alkem Laboratories Ltd(ALKEM) is ₹74331.77Cr.
| Alkem Laboratories Ltd(ALKEM | Price |
|---|---|
52 Week High | ₹6439.9 |
52 Week Low | ₹3447 |
Alkem Laboratories Ltd(ALKEM) share price is ₹6090.3. It is down -5.43% from its 52 Week High price of ₹6439.9
Alkem Laboratories Ltd(ALKEM) share price is ₹6090.3. It is up 76.68% from its 52 Week Low price of ₹3447
| Alkem Laboratories Ltd(ALKEM | Returns |
|---|---|
1 Day Returns | -126.55% |
1 Month Returns | 8.29% |
3 Month Returns | 19.14% |
1 Year Returns | 69.86% |